Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …

Several important findings bearing on the prevention, detection, and management of
hypertension have been reported since publication of the 2017 American College of …

During the recent 30 years, there has been a dramatic increase in knowledge about the role
of aldosterone and the mineralocorticoid receptor (MR) in the pathophysiology of …

Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with
high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint …

Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated
aldosterone production that occurs despite suppression of renin and angiotensin II, and that …

Amiloride is a potassium retaining diuretic and natriuretic which acts by reversibly blocking
luminal epithelial sodium channels (ENaCs) in the late distal tubule and collecting duct …

Aldosterone controls salt–water homeostasis by acting on the mineralocorticoid receptor
(MR), a ligand-activated transcription factor, in kidney epithelial cells. However, it is now …

The pathogenesis of obesity-associated cardiovascular diseases begins long prior to the
presentation of a cardiovascular event. In both men and women, cardiovascular events, and …

Introduction Mineralocorticoid receptor (MR) antagonists (MRAs) provide cardiorenal
protection. However steroidal MRAs might induce hyperkalemia and sex hormone-related …

Renin–angiotensin system inhibitors are recommended for treating hypertension with
chronic kidney disease. The addition of a mineralocorticoid receptor blocker may be one …